WO2004106502A1 - 間葉系幹細胞 - Google Patents
間葉系幹細胞 Download PDFInfo
- Publication number
- WO2004106502A1 WO2004106502A1 PCT/JP2004/007735 JP2004007735W WO2004106502A1 WO 2004106502 A1 WO2004106502 A1 WO 2004106502A1 JP 2004007735 W JP2004007735 W JP 2004007735W WO 2004106502 A1 WO2004106502 A1 WO 2004106502A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- cells
- stem cells
- mesenchymal stem
- cell
- culture
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
- C12N5/0662—Stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/30—Hormones
- C12N2501/38—Hormones with nuclear receptors
- C12N2501/385—Hormones with nuclear receptors of the family of the retinoic acid recptor, e.g. RAR, RXR; Peroxisome proliferator-activated receptor [PPAR]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
- C12N2506/02—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from embryonic cells
Definitions
- the present invention relates to mesenchymal stem cells separated from pluripotent stem cells in vitro, and to a method for preparing such cells.
- Osteoblasts are a general term for progenitor cells before they are differentiated into osteocytes, and are osteogenic mononuclear cells differentiated from osteogenic undivided mesenchymal stem cells (Shinich Harada, et al., Nature 423; 349-355, 2003).
- the mechanism of regulation of the differentiation of undifferentiated mesenchymal stem cells into osteoblasts is unknown, but osteoinductive factors (BMPs) may be involved.
- Embryonic stem cells are pluripotent cells that exist in early embryos, and when injected into other blastocysts, are divided into various cells including germ cells. I can dagger.
- the most studied mouse embryonic stem cells are pluripotent and self-replicating cells established from the inner cell mass in the 3.5-day blastula. This By adding serum and a growth factor called leukemia inhibitory factor (LIF) to a normal culture medium, the cells can be maintained in an undifferentiated state and maintained in growth.
- LIF leukemia inhibitory factor
- embryonic stem cells are forcibly differentiated in vitro (eg, Shinichi ⁇ . Nishikawa, et al., . development 125; 1747-1757 ,. 199.8 ⁇ ; -TOFU Nakano, et al, Science 265; 1098-1101, 1994; Takumi Era, et al .. Blood 95; 870 878,:.: -: see 2.000 ⁇ ) ..
- embryonic stem cells are thought to be completely mature cells through stem cells at various stages of differentiation. However, there are still many unknown points in the process of the differentiation.
- An object of the present invention is to obtain mesenchymal stem cells at an early stage of differentiation from pluripotent stem cells separated in vitro.
- the present inventors have conducted intensive studies and found that when embryonic stem cells are cultured in vitro, mesenchymal stem cells appear at an early stage of differentiation, and this cell population is divided into two special cell surface markers. That is, they found that they expressed platelet-derived growth factor receptor ⁇ (PDGFR a:) and fetal liver kinase-1 (FLK1) in a certain manner, Based on this knowledge Accordingly, the present invention has been completed.
- PDGFR a platelet-derived growth factor receptor ⁇
- FLK1 fetal liver kinase-1
- the present invention provides mesenchymal stem cells differentiated from pluripotent stem cells in vitro.
- the cells are stromal cell-like, PDGFR-positive and FLK1-negative, and do not express Mesp2.
- the cells may have the potential to differentiate into adipocytes, osteoblasts and / or chondrocytes.
- the present invention provides a method for preparing a mesenchymal stem cell comprising the following steps.
- a treatment may be performed to differentiate pluripotent stem cells into mesenchymal stem cells.
- the present invention further provides a method for differentiating the mesenchymal stem cells obtained by the above method into adipocytes, osteoblasts, and chondrocytes.
- adipocytes, osteoblasts and chondrocytes Provides adipocytes, osteoblasts and chondrocytes. ⁇ ;: '....
- FIG. 1 shows the progress of PDGFR expression after induction of differentiation by R.A. :
- Figure 2 shows the progress of PDGFR expression following induction of differentiation into AC adipocytes.
- Figure 3 A—C PDGF Shows the differentiation of Ha positive and negative cells into adipocytes.
- Figure 4 RA (-) shows that PDGFR-positive FLK1-negative cells on day 4 do not differentiate into adipocytes.
- FIG. 6 is a graph comparing the efficiency of adipocyte fractionation according to the time of RA-added caro.
- Fig. 7 shows the self-renewal ability of PDGFR «positive FLK1 negative cells sorted and separated on the 9th day.
- Figure 8 shows that PDGFRa; positive FLK1-negative cells passaged 30 times have the ability to divide into adipocytes.
- Figure 10 Illustrates the cloning process of PDGFRa-positive FLK IP-phagocytic cells.
- Figure 11 shows that all cells of the clonal cell line are PDGFR positive.
- Figure 12 shows that PD GFR-positive FLK1-negative cells differentiate into both adipocytes and osteoblasts.
- mesenchymal cells refers to cells forming mesenchymal tissues such as osteoblasts, chondrocytes, 'myoblasts, fat-adipocytes, stromal cells, and tendon cells, and the like.
- Mesenchymal stem cells that can be differentiated into Mesenchymal cells generated during embryonic development, mesenchymal cells in animal individuals, and live cells derived from pluripotent stem cells in vitro or in vivo
- mesenchymal stem cell means one or more mesenchymal cells: a mesenchymal cell that has the ability to differentiate and self-renew.
- Mesenchymal stem cells have pluripotency that can be differentiated into osteoblasts, chondrocytes, myoblasts, adipocytes, stromal cells, tendon cells, etc., similarly to germ cells. While having pluripotency and self-renewal ability, lineage cells lose their ability as development proceeds, whereas mesenchymal stem cells undergo adult stages It is known to exist for a long time. ; - Therefore, ':.. Between mesenchymal stem cells,' which are expected to be useful for cell transplantation therapy:. '..
- in vitro means that the reaction or culture is performed in vitro, including in embryos. When culturing and / or dividing cells in vitro, any medium, reagent and container suitable for growing cells can be used.
- in vivo means that a reaction or culture is performed in a living body including an embryo, or that a certain phenomenon occurs in a living body.
- pluripotent stem cell means a self-renewable stem cell capable of differentiating into at least two selected from ectoderm, mesoderm and endoderm stem cells, Embryonic stem cells (embryonic stem cells), embryonic germ cells (EG cells), embryonic carcinoma cells (EC cells), multipotent adult progenitor cells (multipotent adult cells) 4007735
- progenitor cells MAP cells
- adult pluripotent stem cells APS cells
- bone marrow stem cells MAP cells
- animals including mammals, birds, and reptiles, including humans, monkeys, mice, rats, rats, hams, cats, guinea pigs, pigs, bush, dogs, cats, cats, goats, sheep
- pluripotent stem cells can be used, they are usually derived from mammals.
- embryonic stem cells are pluripotent cells present in early embryos, and when injected into other blastocysts, are divided into various cells including germ cells. It means a cell that can be ridden. In the present invention, embryonic stem cells newly established from the inner cell mass in the blastula may be used, or an already established cell line may be used.
- the mesenchymal stem cells of the present invention have a stromal cell-like morphology.
- Stromal cells are stars
- D FLK1 is similar to PDGF.R'cr.
- Tyro 'Shinkinase ⁇ is a transmembrane receptor with enzyme activity' (Shalaby, Cell 89;
- a cell expresses a certain molecule
- the mesenchymal stem cells of the present invention do not express genes known as adipocytes, such as PPARa1, PPARa2, adiponectin, and UCP1, and also contain Mesp2, DLL Is Liml, Sox 4. No expression of mesoderm such as mesogenin and neuronal markers such as 0 tX1 and 0 tX2 (Example 6) 6). This means that the mesenchymal stem cells of the present invention are more differentiated than mesoderm stem cells and are in a differentiating stage earlier than 3 T3L 1 cells, which are known preadipocytes. are doing.
- the present inventors have previously shown that when embryonic stem cells were cultured on collagen IV to induce differentiation, PDGFR-positive FLK1-negative cells appeared from the third word after induction, and reached the maximum at the fourth word. And disclosed that these cells include mesodermal stem cells. (Japanese Patent Application No. 20.02-332232).
- the mesenchymal stem cells of the present invention are different from the above-mentioned cells in that they have the ability to differentiate into mesenchymal cells such as adipocytes, osteoblasts and Z or chondrocytes (for example, see Example 4). .
- the above-mentioned cells express a mesodermal marker such as Mesp2, DL Ll, Liml, Sox4, and mesogenin, but do not express the mesenchymal stem cells of the present invention.
- a mesodermal marker such as Mesp2, DL Ll, Liml, Sox4, and mesogenin
- Various other Ma one car gene expression patterns odor, be , present invention
- the cells of the present invention have a stromal cell-like morphology. By examining the presence or absence of the expression of the mesodermal motility gene, the cells of the present invention are referred to as' the cells of the present invention.
- 2002-332232 'cells can be distinguished.
- the mesenchymal stem cells of the present invention can be used for transplantation into mammals or for obtaining cells for transplantation into mammals. Transplantation can be performed on any mammal, including humans.
- a specific operation of culturing the pluripotent stem cell according to the present invention can be performed according to a conventional operation and conditions in the art.
- a conventional operation and conditions in the art For example, Norio Nakatsuji: Experimental Medical Supplement “Experimental Lecture in the Post-Genome Era 4“ Stem Cell Cloning Research Protocol ”, Yodosha (2001), Hogan, G. et al .: Mouse Embryo Manipulation: A Laboratory Manual, Cold Spring Harbor Laboratory Press, Ed. Plainview, NY (1994), Robertson, EJ: Teratogenic cancer and embryonic stem cells, A Practical Approach, IRL Press Oxford, UK (1987).
- the dish is coated with gelatin, and the dish is seeded with embryonic stem cells at a concentration of 10.0 / cm 2 , and cultured in a 37 C, 5% CO 2 incubator. Change the medium once the next day, and when it becomes confluent on the second day, rinse once or twice with phosphate buffered saline, and then add a sufficient amount of 0.2.5% (W / V) Add to cover the cell layer and leave for about 5 minutes. Remove the trypsin-10 solution, add an appropriate amount of embryonic stem cell culture medium, and separate from the dish by pipetting. From this cell suspension, the cells are sedimented, usually by centrifugation.
- the precipitated cells were resuspended in media for embryonic stem cell culture, again .1 '':; ⁇ ' ⁇ :,' ⁇ : 0 ',: 0,0.0: pieces / c m' of 2 Seed at a concentration of gelatin-coated rice dish :: culture;
- pluripotent stem cell maintenance medium is usually used for cell culture. Serum to minimum medium, to: LIF, L-Gludamine, ... 2-mercaptosol solution, etc. 85% KNOCKOUT D-M ring ' .. 15% FBS ⁇ . 10 4 ⁇ : ⁇ 2: —M, E,: 2 mM L-glutamine, 0.1 ′ mM NE: AA, 1000 20 U /, ml-LIF. ::.: ':::::
- the pluripotent stem cells are cultured in a pluripotent stem cell sorting medium excluding LIF from the above pluripotent stem cell maintenance medium.
- a pluripotent stem cell sorting medium excluding LIF from the above pluripotent stem cell maintenance medium.
- LIF pluripotent stem cell maintenance medium.
- the pluripotent stem cells are cultured in a pluripotent stem cell dividing medium, the 25 pluripotent stem cells are released from an undifferentiated state and start to differentiate into various cells.
- the number of days of culture the number of days of culture in a culture medium for dividing pluripotent stem cells is used.
- the culture medium for maintaining pluripotent stem cells and the culture medium for differentiation can be supplemented with other substances useful for culturing, such as antibiotics. 7735
- each component of the culture medium is used after sterilizing by an appropriate method.
- the method for preparing mesenchymal stem cells of the present invention includes a step of confirming the appearance of stromal cells.
- "appearance of stromal cells” means that the cells in stromal cell-like morphology account for 1% or more, preferably 5% or more, and most preferably 10% or more of the whole cells. Under normal culture conditions that do not maintain an undivided state, stromal cell-like cells begin to appear around the fifth day of culture. The morphology of the cells can be observed with a general optical microscope, phase contrast microscope, 'inverted phase contrast microscope, or the like.
- the method for preparing mesenchymal stem cells of the present invention takes a part of the sorted and separated cells, and selects at least one selected from the group consisting of Mesp2, Liml and mesodinin. The step of confirming that the germ layer gene is not expressed is further included. The presence or absence of the germ layer expression gene is determined by RT PCR Sozan ⁇ mouth. • '; Petit method: DNA chip method, enzyme immunoassay: (E.:L:IZ':A and anti- It may be confirmed by any method common in the art, such as body staining, etc. Usually, it is preferable to confirm by the 'RT' method.
- the antibody used to select and separate the cells in the method for preparing mesenchymal stem cells of the present invention is a polyclonal or monoclonal antibody or a monoclonal antibody.
- monoclonal antibodies are preferred.
- Such antibodies can be prepared by those skilled in the art with reference to the methods described in Examples-, but commercially available ones may be used.
- Anti-PDGFR monoclonal antibody (Part No. 5,58774 :) and anti-FLK1 monoclonal antibody (Part No. 555308) are commercially available from BD Pharmingen and are readily available. ⁇ '
- FACS fluorescence-activated Celso overnight
- FACS usually includes a flow cytometer, laser generator, optics, data processor, and cell sorter.
- the functions of FACS are automatic separation of fluorescently labeled cells and computer analysis of fluorescence intensity.
- FACS irradiates cells labeled with a specific substance with a laser beam in the middle of a narrow channel, and measures scattered light (forward scattered light and side scattered light) and fluorescence signal information for each individual cell. , The results can be displayed, for example, as a frequency distribution, and cells that emit specific signal information can be sorted.
- the FACS device is commercially available from Becton-Dickinson et al. And can be operated by those skilled in the art according to the manufacturer's instructions.
- the method for selecting cells in the present invention the method using an antibody has been described in detail, but it is also possible to select cells based on the presence of mRNA on each cell surface marker.
- a treatment for promoting the differentiation of pluripotent stem cells may be performed.
- the target mesenchymal stem cells appear during the differentiation process.
- pluripotent stem cells are used as a treatment for promoting the division of pluripotent stem cells.
- a process for differentiating cells into fat cells may be employed.
- pluripotent stem cells do not need to be completely differentiated into adipocytes, and the target mesenchymal stem cells appear in the middle of the differentiation process.
- Differentiation may be performed by any method known in the art, but "" Typically, the method described in '' Developmental Cell 4 ;; 119-129, 2003 ⁇ Jun Nakae et al. Differentiate, for example, for embryonic stem cells, 90% . ⁇ ; 10% FBS,
- embryos may be formed and then differentiated.
- treatment for differentiating pluripotent stem cells into osteoblasts may be employed as treatment for promoting pluripotent stem cells to differentiate mesenchymal stem cells.
- Book In the present invention it is not necessary to completely divide the pluripotent stem cells into osteoblasts, and the target mesenchymal stem cells appear during the siding process. May be differentiated by any method known in the art.
- embryonic stem cells 90% aMEM, 10% FBS , 5x 10- 5 M 2- ME, embryonic stem cells fraction containing 2 mM L-glutamine Pluripotent stem cells are cultured on a gelatin-coated dish using a medium for baking, and from day 2 of culture, BMP-4, ascorbic acid monophosphate, dexamethasone and? -Glycemic phosphate To the culture medium and incubate.
- BMP-4 ascorbic acid monophosphate
- dexamethasone and? -Glycemic phosphate To the culture medium and incubate.
- a process for differentiating pluripotent stem cells into chondrocytes may be employed.
- 'In the present invention ' pluripotent ''.
- the' mesodermal stem cells previously disclosed by the present inventors were prepared by 'adding trans-W thiocyanic acid' to the culture medium. Including PDGFR
- the present invention further provides a method for preparing an adipocyte, comprising a process of differentiating the mesenchymal stem cell of the present invention into an adipocyte.
- adipocyte for example, as described in Examples, dexamethasone of 5 ⁇ g / ml of insulin, in a medium for embryonic stem cell differentiation containing 90% MEM, 10% FBS 2 mM L-glucan honey, as described in Examples Culturing mesenchymal stem cells on collagen IV coated dish in a medium supplemented with 5Q0 M 3-isobutyl-11-methylxanthine and 1 M troglitazone.
- Adipocytes can be confirmed by cell staining using an oil pellet.
- the present invention further provides a method for preparing osteoblasts, comprising a process of differentiating the mesenchymal stem cells of the present invention into osteoblasts.
- the processing is performed, for example, as described in 1 ng / ml: BMP-4, 50 ⁇ M ascorbic acid monophosphate in medium for embryonic stem cell sorting containing 0% HI M, 10% FBS 2 mM L-glutamine Including culturing mesenchymal stem cells on gelatin coated dishes in a medium supplemented with acid, 0.1 / M dexamethasone, and 10 mM /?-Glycerophosphate. Osteoblasts can be confirmed by cell staining using alizarin red.
- the present invention further provides a method for preparing chondrocytes, comprising a process of differentiating the mesenchymal stem cells of the present invention into chondrocytes.
- the treatment may be performed, for example, in the case of embryonic stem cells, a medium obtained by adding 90% dexamethasone to an embryonic stem cell sorting medium containing 90% a MEM, 0.10% FBS, and 2 mM L-glucamine. Culturing mesenchymal stem cells. Chondrocytes can be identified by cell staining using Alcian Pebble o '
- the present invention provides a method for treating a mammalian disorder, comprising: transplanting chondrocytes into a mammal, including: mesenchymal stem cells of the present invention: adipocytes, osteoblasts, and omama.
- a mammal including: mesenchymal stem cells of the present invention: adipocytes, osteoblasts, and omama.
- cartilage such as osteoarthritis of the knee may be destroyed: for the treatment of various diseases, from the mesenchymal stem cells of the present invention, a large amount of chondrocytes are differentiated into the joint. This chondrocyte can be transplanted.
- the mesenchyme of the present invention are differentiated into the joint.
- Intravenous injection of stem cells s Can stimulate myocardial regeneration.
- the treatment method of the present invention can be performed on any mammal, including humans. ⁇ " ⁇ ⁇ ⁇ ⁇ " ⁇ ⁇ To ''.
- the present invention also provides a drug screening method using the mesenchymal stem cells, adipocytes, osteoblasts and Z or chondrocytes of the present invention.
- the mesenchymal stem cells of the present invention are cultured in a medium supplemented with candidate substances, and a substance that separates these cells into osteoblasts is screened. .
- 'Culture medium for maintaining embryonic stem cells is 85% KN ⁇ K 0 ⁇ : DH DH ⁇ ⁇ % 5%
- FB S ⁇ 10-' 4 ⁇ ⁇ 2 ⁇ ⁇ 2 mM L-glutamine, 0. lmM EA A, OO ⁇ iii / iiil L PP.
- Pot embryonic stem cells were used: the mouse 129 v system integration from Me CCEfc stem cells (Robertson, ⁇ 'et' al 'Naturae .323,: 445-448, 1986 o..)':. '- way:, ⁇ '' ::: ⁇ ., ' ⁇ : ::.:...' ;
- composition of the medium for embryonic stem cell differentiation was 90% MEM, 1: 0% F, B'S, 5 ⁇ 1 1: 1-5 ⁇ 2—ME, 2 mM L-glutamine. '
- Collagen IV coated 10 cm dishes were seeded with 3 ⁇ 10 3 CC E embryonic stem cells. On days 5 and 7, the medium was replaced with the medium for embryonic stem cell differentiation.
- Induction into adipocytes was performed by adding the reagents shown in Table 3 to a culture medium for embryonic stem cell sorting containing 2-ME. The culture was performed on a culture plate coated with collagen IV. Induction into osteoblasts was performed by adding the reagents in Table 4 to a medium for embryonic stem cell differentiation without 2-ME. The cultivation was completed on culture plates that had been reduced with gelatin. Table 4;
- ⁇ Induction of osteocytes was performed by adding lM M dexazone to a medium for embryonic stem cell differentiation not containing 2-ME. : ..: ' ⁇ :::, Reference example a .. Preparation of body:.::::, ..'.
- a monoclonal antibody 'recognizing the extracellular portion of each molecule was prepared by a method well known to those skilled in the art. Specifically, the procedure was as follows. The cDNA of the extracellular portion of mouse PDGFR was amplified using PCR, and this DNA sequence was combined with the DNA sequence of the Fc portion of human IgG1 to prepare a fused cDNA. This cDNA was introduced into COS 1 cells, and the fusion protein in the culture supernatant was recovered using a Protein A column. Rats were immunized with the recovered protein. After the immunization, the spleen was collected, and the spleen cells were fused with the myeloma cell line X63. Ag8 to prepare hybridoma cells.
- antibodies that react with Balb / c-3T3 cells expressing the fusion protein and PDGFR were selected from the antibodies contained in the culture supernatant of the hybridoma cells.
- a clone of the hybridoma cell was identified. TJP2004 / 007735
- Table 5 The reagents in Table 5 were used. Table 5 To 900 ml of deionized water, 100 ml of 1 Ox Hangs buffer and 10 g of BSA (final concentration 1%) were added and mixed well. BSA dissolved; filter sterilized using 0.2 /: m fill filter. '''b. ⁇ method ..:.
- the anti-PDGFR antibody was labeled with biotin, and the anti-FLK1 antibody was labeled with phycoerythrin (both were purchased from Molecular probe), and used for the following staining.
- mouse serum 10 ⁇ 1 / 10 6 cells was 20 minutes Inkyu Bae ten on ice.
- 10 ng to .500 ng of each antibody was added and incubated on ice for 20 minutes. After 20 minutes, the cells were washed once with 1% BSA Hanks buffer.
- the cells were resuspended in 5001 1% BSA Hanks buffer containing streptavidin allopycocyanine (APC; Beet-Dickinson) and incubated on water for 20 minutes. Finally washed twice with 1% BSA Hanks buffer, and dissolved in 1% BSA Hanks buffer 1 ml of per 10 6 cells were used for cell sorting.
- APC streptavidin allopycocyanine
- Example 1 Appearance time of DGFR-positive FLK1-negative cells
- the morphology of these cells is very similar to the stromal cells, which are mesenchymal cells derived from bone marrow. and I had '. further; to flag the, ⁇ staining continued culture of the cell where the, the, the appearance of fat cells has been confirmed (Oi-les-Red by fat-stained image:. left)..'; example 3.
- CCE embryonic stem cells were cultured in the same manner as in Example 2, and the adipocytes were subjected to filtration treatment as shown in FIG. 2A.
- PDGR-positive and FLK1-negative cells were selected and separated using FacsVantage. These cells were cultured for 7 days after selection and separation, and fat staining with Oil Red was performed.
- Fig. 3A it was found that cells in the PDGFR-positive FLK1-negative fraction differentiated into adipocytes with high efficiency (Fig. 3A). These cells had large amounts of the adipocyte-specific substance triglyceride (FIG. 3B).
- RT- PCR was used to examine the expression of fat-specific motility in cells cultured for 3 days and 7 days after selection and separation.
- Expression of adiponectin and PPRa Figure 3C.
- PDGFR-negative FLK1-negative cells were selected and separated, cultured for 7 days, and subjected to oil red fat staining, triglyceride measurement, and RT-PCR.
- FIGS. 3A-C no adipocytes appeared from PD GFR P-phagocytic cells.
- Example 4 Culture PDGFRa-positive cells on day 4 do not have the ability to bind to adipocytes.
- CCE embryonic stem cells were cultured in a medium for RA-free embryonic stem cell sorting.
- PDGFR-positive FLK1-positive cells, and PDGF.Ra-positive FLK1-negative cells were selected and separated using FacsVantage. After culturing these cells under conditions for inducing differentiation into adipocytes for an additional 14 days ”(until day 23 of culture), fat staining was performed. ⁇ ⁇ . 'As a result, it was found that the differentiation ability of both rain cells and adipocytes was extremely low.
- ⁇ ' -CRA embryonic stem cells are cultured in embryonic stem cell sorting medium containing no RA, and cultured for 4 days.:-Using FacsVahtage on eyes :: PD.GFRo: positive FLK1' negative Cells were sorted and separated.
- Example 6 PDGFR-positive FLK1-negative cells do not express adipocytes.
- CCE embryonic stem cells were cultured and applied to adipocytes as shown in Figure 2A. Differentiation treatment was performed. On day 9 of the culture, PDGFR-positive and FLK1-negative cells were selected and separated using FacsVantage. The gene expression of these cells was examined by RT-PCR. As shown in Fig. 5, no adipocyte marker was expressed, and no neuronal cell was expressed. The cell morphology (see Example 2) and this pattern of gene expression revealed that the cells were in a differentiation stage prior to adipocytes.
- Example 7. Incubation of RA on the second and third days of culture allows PDGFRa-positive FLK1-negative cells to differentiate efficiently.
- CCE embryonic stem cells were cultured in the embryonic stem cell differentiation medium at various times as shown in Figure 6.
- RA was added, and on day 9 of culture, PDGFR-positive-FLK1-negative ... ' ⁇ ⁇ ' sex cells were selected and separated using FacsVantage. ⁇ Cells were cultured for 9 hours under conditions of inducing adipocyte differentiation, and the amount of neutral fat in the cells was measured. Starting to induce the differentiation of embryonic stem cells, 'Day 2-Day, Day 3 + Day, r 4 ⁇ Day': Add RA to the eye: PDG FR 'positive' most efficiently L'K'.l negative cells appeared (Fig. 6) '. At other times. Addition of RA induces differentiation into these cells; “ta", but ". Efficiency is less than 2.” Bonito. ": ⁇
- Example 8 Self-renewal ability of .PD GFH ⁇ -positive FLK1-negative cells
- CGE embryonic stem cells were cultured and subjected to adipocyte differentiation as shown in the figure as in Example 2. 'On day 9 of culture, PD G.F R was used for positive FL using FacsVantage.
- K1-negative cells were sorted and separated. These cells were passaged 30 times in a medium for the differentiation of embryonic stem cells containing: 2-ME, and the number of cells was counted. As shown in Fig. 7, the proliferative power did not decrease after 30 passages, but increased. Cells at passages 20 and 30 were cultured in a medium for adipocyte differentiation. The cells were stained with Oil Red for fat, and as shown in FIG. 8, many cells differentiated into fat cells. Therefore, it was suggested that these cells have the ability to self-renew while maintaining differentiation ability.
- Example 9 Differentiation ability of PDGFR-positive FLK1-negative cells to osteoblasts PT / JP2004 / 007735
- CCE embryonic stem cells were cultured and subjected to an adipocyte differentiation treatment as shown in FIG. 2A.
- PD GFR-positive and FLK1-negative cells were selected and separated using FacsVantage. These cells were cultured under the conditions for inducing osteoblast differentiation described in Reference Example 2 for 16 days (that is, cultured for 25 days), and the cells were collected and subjected to RT-PCR. These cells expressed osteoblast-specific molecules (Fig. 9, upper left). The cells on the 25th day of the culture and the cells on the 42nd day of the further culture were stained with an osteoblast-specific stain, alizarin red (FIG. 9, lower left).
- 'Differentiated 'FacsVantage ⁇ used for culture. 9; BGFRa-positive FL ! K1 P inoculated cells were sorted and separated. These cells were cultured under the conditions of chondrocyte differentiation described in Reference Example 2 ⁇ : Induction for 0.21 days (that is, cultured for 30 days), the cells were collected, and RT-PC: ';, R was performed. "'These cells expressed chondrocyte-specific molecules' ( Figure 9, top right)
- CCE embryonic stem cells were cultured and subjected to adipocyte differentiation as shown in FIG. 2A.
- PD GFR-positive FL ⁇ K1-negative cells were selected and separated using FacsVantage. These cells were subcultured 20 times. Then 0 ..
- the cells were seeded on a flat-bottom 96-well plate at 3 cells / well and cultured in a medium for embryonic stem cell sorting. As the cells grew and became confluent, the culture scale was raised as needed. Finally, the cells were grown to an amount that can be cultured in a 10 cm dish, and the cloned cell lines were preserved. 28 clone cell lines were established (Fig. 10). Each of these cloned cell lines was PDGFR-positive ( Figure 1). 4007735
- the stromal cell-like form of PDGFR «P-easy FLK 1'-negative cells of the present invention has both pluripotency and self-renewal ability. It became clear that it was. '' Industrial use 3 ⁇ 4Possibility ::.
- the mesenchymal stem cells of the present invention have the ability to differentiate from mesenchymal cells such as adipocytes, osteoblasts, and chondrocytes.
- the mesenchymal stem cells of the present invention and cells differentiated therefrom can be used for the development of drugs targeting them.
- fat cells are useful in developing drugs for treating diabetes and hyperlipidemia.
- these cells can be used by cells that produce biomaterials, such as biomaterials, and can be used for surgery or cell transplantation, such as breast formation using adipose tissue. Applications are also possible.
- the 3T3L1 cell line is known as a cell line that is highly efficient for adipocytes, but the mesenchymal stem cell of the present invention is characterized by the fact that 3T3L1 It has the advantages of being in a differentiation stage earlier than cells, and being not a cancerous cell line.
- Osteoblasts can also be used, for example, for screening agents for treating and / or preventing osteoporosis. By implanting osteoblasts and chondrocytes into experimental animals, basic research on regeneration and medical treatment can be performed.
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- General Health & Medical Sciences (AREA)
- Diabetes (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Microbiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Developmental Biology & Embryology (AREA)
- Rheumatology (AREA)
- General Chemical & Material Sciences (AREA)
- General Engineering & Computer Science (AREA)
- Cell Biology (AREA)
- Biochemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Description
Claims
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2005506565A JPWO2004106502A1 (ja) | 2003-05-28 | 2004-05-28 | 間葉系幹細胞 |
EP04735372A EP1627913A4 (en) | 2003-05-28 | 2004-05-28 | MESENCHYMAL STEM CELLS |
US10/558,308 US20070053885A1 (en) | 2003-05-28 | 2004-05-28 | Mesenchymal stem cell |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2003-150690 | 2003-05-28 | ||
JP2003150690 | 2003-05-28 | ||
JP2004129857 | 2004-04-26 | ||
JP2004-129857 | 2004-04-26 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2004106502A1 true WO2004106502A1 (ja) | 2004-12-09 |
Family
ID=33492427
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2004/007735 WO2004106502A1 (ja) | 2003-05-28 | 2004-05-28 | 間葉系幹細胞 |
Country Status (4)
Country | Link |
---|---|
US (1) | US20070053885A1 (ja) |
EP (1) | EP1627913A4 (ja) |
JP (1) | JPWO2004106502A1 (ja) |
WO (1) | WO2004106502A1 (ja) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005108557A1 (ja) * | 2004-04-26 | 2005-11-17 | Riken | 前駆間葉系幹細胞 |
JP2007228873A (ja) * | 2006-03-01 | 2007-09-13 | Gunze Ltd | 間葉系幹細胞の分化を計測する方法 |
JP2009535347A (ja) * | 2006-04-28 | 2009-10-01 | テュレーン・ユニバーシティ・ヘルス・サイエンシーズ・センター | 糖尿病の治療方法 |
WO2009128533A1 (ja) * | 2008-04-18 | 2009-10-22 | 国立大学法人名古屋大学 | 間葉系幹細胞およびその生産方法 |
JP2013507981A (ja) * | 2009-10-27 | 2013-03-07 | エスエヌユー アールアンドディービー ファウンデーション | ヒト万能幹細胞から中胚葉幹細胞を生産する方法、及びその中胚葉幹細胞 |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7807458B2 (en) | 2003-01-30 | 2010-10-05 | The United States Of America As Represented By The Secretary Of The Department Of Veterans Affairs | Multilineage-inducible cells and uses thereof |
ATE470199T1 (de) * | 2003-04-24 | 2010-06-15 | Koninkl Philips Electronics Nv | Eingriffsfreie links-herzkammervolumenbestimmung |
EP1981970A4 (en) | 2006-01-11 | 2009-10-21 | Technion Res & Dev Foundation | TISSUE CONSTRUCTION TISSUE TREATMENT DERIVED FROM A HUMAN EMBRYONIC STEM CELL |
EP2377924A1 (en) | 2006-04-14 | 2011-10-19 | Advanced Cell Technology, Inc. | Hemangio-colony forming cells |
WO2007122233A1 (en) * | 2006-04-25 | 2007-11-01 | Vrije Universiteit Brussel | Preparation of mesenchymal progenitor cells, particularly osteogenic progenitor cells |
EP2920299A4 (en) * | 2012-11-15 | 2016-05-18 | Int Stem Cell Corp | DIFFERENTIATION OF HUMAN FIBROBLASTING CELLS |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2004159614A (ja) * | 2002-11-15 | 2004-06-10 | Inst Of Physical & Chemical Res | 表面細胞マーカーを指標に精製した中胚葉系幹細胞 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20020142457A1 (en) * | 1999-12-28 | 2002-10-03 | Akihiro Umezawa | Cell having the potentiality of differentiation into cardiomyocytes |
JPWO2004104184A1 (ja) * | 2003-05-20 | 2006-07-20 | 独立行政法人理化学研究所 | 内胚葉系幹細胞の調製 |
JP2005304443A (ja) * | 2004-04-26 | 2005-11-04 | Institute Of Physical & Chemical Research | 前駆間葉系幹細胞 |
-
2004
- 2004-05-28 EP EP04735372A patent/EP1627913A4/en not_active Withdrawn
- 2004-05-28 WO PCT/JP2004/007735 patent/WO2004106502A1/ja active Application Filing
- 2004-05-28 US US10/558,308 patent/US20070053885A1/en not_active Abandoned
- 2004-05-28 JP JP2005506565A patent/JPWO2004106502A1/ja not_active Withdrawn
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2004159614A (ja) * | 2002-11-15 | 2004-06-10 | Inst Of Physical & Chemical Res | 表面細胞マーカーを指標に精製した中胚葉系幹細胞 |
Non-Patent Citations (4)
Title |
---|
KATAOKA H. ET AL: "Expressions of PDGF receptor alpha, c-Kit and FLK1 genes clustering in mouse chromosome 5 define distinct subsets of nascent mesodermal cells", DEV GROWTH DIFFER, vol. 39, no. 6, 1997, pages 729 - 740, XP002980493 * |
NAKAYAMA N. ET AL: "Macroscopic cartilage formation with embryonic stemcell-derived mesodermal progenitor cells", JOURNAL OF CELL SCIENCE, vol. 116, no. 10, 15 May 2003 (2003-05-15), pages 2015 - 2028, XP002980492 * |
See also references of EP1627913A4 * |
YOSHIDA H. ET AL: "Hematopoietic Tissues, as a Playground of Receptor Tyrosine Kinases of the PDGF-Receptor Family", DEVELOPMENTAL AND COMPARATIVE IMMUNOLOGY, vol. 22, no. 3, 1998, pages 321 - 332, XP002980494 * |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005108557A1 (ja) * | 2004-04-26 | 2005-11-17 | Riken | 前駆間葉系幹細胞 |
JP2007228873A (ja) * | 2006-03-01 | 2007-09-13 | Gunze Ltd | 間葉系幹細胞の分化を計測する方法 |
JP2009535347A (ja) * | 2006-04-28 | 2009-10-01 | テュレーン・ユニバーシティ・ヘルス・サイエンシーズ・センター | 糖尿病の治療方法 |
WO2009128533A1 (ja) * | 2008-04-18 | 2009-10-22 | 国立大学法人名古屋大学 | 間葉系幹細胞およびその生産方法 |
JP2013507981A (ja) * | 2009-10-27 | 2013-03-07 | エスエヌユー アールアンドディービー ファウンデーション | ヒト万能幹細胞から中胚葉幹細胞を生産する方法、及びその中胚葉幹細胞 |
JP2015107124A (ja) * | 2009-10-27 | 2015-06-11 | エスエヌユー アールアンドディービー ファウンデーション | ヒト万能幹細胞から中胚葉幹細胞を生産する方法、及びその中胚葉幹細胞 |
Also Published As
Publication number | Publication date |
---|---|
US20070053885A1 (en) | 2007-03-08 |
JPWO2004106502A1 (ja) | 2006-07-20 |
EP1627913A1 (en) | 2006-02-22 |
EP1627913A4 (en) | 2007-08-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Raynaud et al. | Comprehensive characterization of mesenchymal stem cells from human placenta and fetal membrane and their response to osteoactivin stimulation | |
RU2465325C2 (ru) | Способ получения мезенхимной клетки, способ получения зуба и мезенхимная клетка для формирования зуба | |
EP3124600B1 (en) | Method for generating a cell condensate for self-organisation | |
CN106661552B (zh) | 心脏细胞培养材料 | |
KR20150083440A (ko) | 순수 영양막층으로부터 유래된 줄기세포 및 이를 포함하는 세포치료제 | |
WO2004106502A1 (ja) | 間葉系幹細胞 | |
Ibarra-Ibarra et al. | Improved efficiency of cardiomyocyte-like cell differentiation from rat adipose tissue-derived mesenchymal stem cells with a directed differentiation protocol | |
JP7069492B2 (ja) | 類似間葉系幹細胞の製造方法及びこれにより製造された類似間葉系幹細胞 | |
KR20120006386A (ko) | 1기 태반조직 유래 줄기세포 및 이를 함유하는 세포치료제 | |
US20070218548A1 (en) | Mesenchymal Stem Cell Processor | |
JP7198524B2 (ja) | スフェロイドの製造方法および多能性幹細胞マーカーを発現させる方法 | |
US20210363485A1 (en) | Stepwise method of producing various types of cells from pluripotent stem cells | |
JP4368572B2 (ja) | 表面細胞マーカーを指標に精製した中胚葉系幹細胞 | |
KR20130085308A (ko) | 인간 배아줄기세포 유래 혈관주위 전구세포의 제조방법 및 이를 포함하는 세포치료 조성물 | |
JP2008141973A (ja) | 心筋細胞の培養増殖法 | |
JP2008161183A (ja) | 内皮細胞および心筋細胞用培地mv06 | |
Thelen | Alternatives for Improving the Adipogenic Potential in Cellular Models of Perivascular Adipose Tissue | |
고동우 | Studies on Improvement of Bone Marrow-derived Cell Establishment and Manipulation in Chicken | |
Zeng et al. | Differentiation and dynamic analysis of primitive vessels from embryonic stem cells | |
Lee | Cytotherapeutics: Emerging Tool of Clinical Application in Veterinary Sciences | |
Meier | Endothelial and epithelial differentiation potential of human adult stem cells PSC and MSC and the relation of ZO-1 isoform ratio to epithelial differentiation in Caco-2 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DPEN | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed from 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2005506565 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2007053885 Country of ref document: US Ref document number: 10558308 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2004735372 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2004735372 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 10558308 Country of ref document: US |